FF305 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年11月18日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) ...

Summary of Conference Call Notes Company and Industry Overview - **Company**: 和铂医药 (HaploMed) and its subsidiary 诺纳生物 (Nona Bio) - **Industry**: Biopharmaceuticals, focusing on innovative drug development and clinical research Key Points and Arguments Nona Bio's Strategic Positioning - Nona Bio aims to provide integrated delivery services, differentiating itself from traditional CROs by offering comprehensive solutions rather than fragmented services [2][5] - The company has four key technology platforms: 1. HMI humanized transgenic mouse platform 2. ADC/RDC/AOC delivery systems 3. Novel in vivo CAR systems 4. AI research platform [2][6] Future Expansion Plans - Nona Bio plans to expand from the Discovery phase to CMC and clinical concept validation stages over the next three years [3][8] - Collaborations with top GLP and CDMO companies are intended to enhance capabilities in GLP and high-end formulation development [3][8] AI Integration in Drug Development - AI is a crucial part of Nona Bio's strategy, with plans to establish an AI innovation center in Shanghai to enhance drug discovery efficiency [7][10] - The company aims to utilize accumulated high-quality data to improve antibody discovery processes [7][10] Clinical Development of 4,003 Project - The 4,003 project, a Treg cell-clearing therapy, has shown significant efficacy in preclinical studies, demonstrating a potency 100 times greater than the control group [2][21] - In clinical trials for MSS colorectal cancer, the objective response rate (ORR) was 34.8%, with a 12-month overall survival (OS) rate of 84% [3][22] Market Potential and Unmet Needs - Colorectal cancer (CRC) represents a significant market opportunity, with approximately 1.9 million new cases globally each year, and 95% of patients being MSS CRC [33][34] - The 4,003 project addresses unmet needs in MSS CRC, where current treatments are limited [22][34] Safety and Efficacy of 4,003 - The safety profile of 4,003 is comparable to existing checkpoint inhibitors, with manageable adverse events primarily at grade 1 or 2 [23][24] - The project is positioned to explore further indications beyond colorectal cancer, maximizing its therapeutic potential [25][26] Competitive Landscape - Nona Bio's 4,003 project is distinct from traditional CTLA-4 therapies, focusing on Treg cell clearance rather than blocking CTLA-4 function [27][28] - The company is actively seeking partnerships to enhance the development and commercialization of HBM 403, retaining rights in key markets like China [29] Financial Projections - Nona Bio aims to achieve normalized revenue of 1 billion RMB by 2028, with projected growth rates of 50%-80% in 2026-2027 [12][19] Workforce Expansion - The company plans to double its workforce by 2026 and again by 2028 to support business growth [16] Additional Important Insights - Nona Bio's unique advantage lies in its ability to generate high-quality data through its proprietary platforms, enhancing AI model training and drug discovery efficiency [14][15] - The company does not currently have plans for a separate IPO and focuses on its core competencies in preclinical stages [35][36]

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on November 17, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent on buybacks [1]. Group 1: Buyback Details - China Feihe (06186) repurchased 10.81 million shares for a total of 47.19 million yuan, representing 1.532% of its total share capital [2]. - COSCO Shipping Holdings (01919) repurchased 3 million shares for 41.62 million yuan, accounting for 1.083% of its total share capital [2]. - Sinopec Limited (00386) repurchased 3.79 million shares for 16.73 million yuan, which is 0.120% of its total share capital [2]. Group 2: Other Notable Buybacks - Lianlian Digital (02598) repurchased 1.71 million shares for 13.67 million yuan, representing 2.608% of its total share capital [2]. - Linklogis Technology (09959) repurchased 2.65 million shares for 7.40 million yuan, accounting for 4.885% of its total share capital [2]. - Jitu Express (01519) repurchased 640,000 shares for 6.25 million yuan, which is 0.041% of its total share capital [2]. Group 3: Additional Companies - Mengniu Dairy (02319) repurchased 200,000 shares for 2.98 million yuan, representing 0.660% of its total share capital [2]. - Kangning Jereh Pharmaceutical (09966) repurchased 350,000 shares for 3.42 million yuan, accounting for 0.211% of its total share capital [3]. - Huajian Medical (01931) repurchased 593,000 shares for 3.64 million yuan, which is 0.660% of its total share capital [3].

智通财经APP讯，和铂医药-B(02142)发布公告，该公司于2025年11月17日斥资137.5万港元回购10万股 股份，每股回购价格为13.68-13.8港元。 ...

Core Viewpoint - The company, Heptagon Pharmaceuticals-B (02142), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - The company will repurchase 100,000 shares at a total cost of HKD 1.375 million [1] - The buyback price per share ranges from HKD 13.68 to HKD 13.80 [1]

格隆汇11月17日丨和铂医药-B(02142.HK)公告，11月17日耗资137.5万港元回购10万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年11月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | | 是 | | | | | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | | | ...

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on November 13, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent on buybacks, amounting to 20 million shares and 87.858 million yuan respectively [1][2]. Group 1: Buyback Details - China Feihe (06186) repurchased 20 million shares for 87.858 million yuan, with a year-to-date total of 117 million shares, representing 1.294% of its total share capital [2]. - COSCO Shipping Holdings (01919) repurchased 3 million shares for 42.9502 million yuan, with a year-to-date total of 25.188 million shares, accounting for 0.875% of its total share capital [2]. - China International Marine Containers (02039) repurchased 2.8054 million shares for 20.01 million yuan, with a year-to-date total of 3.66303 million shares, representing 1.190% of its total share capital [2]. Group 2: Other Notable Buybacks - Sinopec Limited (00386) repurchased 3.468 million shares for 15.3039 million yuan, with a year-to-date total of 139 million shares, accounting for 0.110% of its total share capital [2]. - Yip's Chemical Holdings (06826) repurchased 39,500 shares for 1.1077 million yuan, with a year-to-date total of 580,100 shares, representing 1.482% of its total share capital [3]. - Kangji Medical Holdings (01681) repurchased 20 million shares for 300,000 yuan, with a year-to-date total of 9.898 million shares, accounting for 11.627% of its total share capital [3].

Core Viewpoint - The company, He Bo Pharmaceutical-B (02142), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Category Company Actions - The company plans to repurchase 200,000 shares at a total cost of HKD 2.7011 million [1] - The buyback price per share ranges from HKD 13.24 to HKD 13.67 [1] Financial Implications - The total expenditure for the share buyback reflects the company's strategy to enhance shareholder value [1]

Core Viewpoint - The company, Heptagon Pharmaceuticals-B (02142), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Categories Share Buyback Details - The company will repurchase 200,000 shares at a total cost of HKD 2.7011 million [1] - The buyback price per share ranges from HKD 13.24 to HKD 13.67 [1]